Amgen Cuts Repatha Price 60% on New Website After Trump Pressure

Oct. 6, 2025, 1:00 PM UTC

Amgen Inc. is the latest drugmaker to offer its medicines at a discount for cash-paying patients, following President Donald Trump’s demands that pharmaceutical companies slash their prices in the US.

Patients are now able to buy the cholesterol-lowering shot Repatha for $239 a month, a discount of nearly 60%, directly through a new, online platform called AmgenNow, the company said Monday. It also plans to make AmgenNow accessible via the newly announced TrumpRx website.

Repatha’s price has already come down substantially since its approval in 2015. The current list price is about $573 for a 30-day supply, or $6,876 ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.